FDA Approved: SIMVASTATIN — Supplemental Application (WATSON LABS TEVA)

View source ↗

Summary

A supplemental application approval for simvastatin by Watson Labs Teva, indicating a formulation/label change under an ANDA submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Hypercholesterolemia

Drugs mentioned

• SIMVASTATIN (SIMVASTATIN)

Snippet

SUPPL AP for SIMVASTATIN (SIMVASTATIN)